Recap: OpGen Q2 Earnings

Shares of OpGen OPGN rose 4.98% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 226.67% over the past year to ($0.49), which beat the estimate of ($0.51).

Revenue of $1,188,000 up by 17.62% from the same period last year, which missed the estimate of $1,200,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

OpGen hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 12, 2020

Time: 04:30 PM

ET Webcast URL: http://public.viavid.com/index.php?id=141125

Technicals

Company's 52-week high was at $12.80

52-week low: $0.24

Price action over last quarter: Up 25.00%

Company Profile

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledgebase.